Drug Shortage Report for TEVA-BUPRENORPHINE/NALOXONE
Report ID | 144704 |
Drug Identification Number | 02453908 |
Brand name | TEVA-BUPRENORPHINE/NALOXONE |
Common or Proper name | TEVA-BUPRENORPHINE/NALOXONE |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | NALOXONE BUPRENORPHINE |
Strength(s) | 0.5MG 2MG |
Dosage form(s) | TABLET |
Route of administration | SUBLINGUAL SUBLINGUAL |
Packaging size | 30 |
ATC code | N07BC |
ATC description | DRUGS USED IN ADDICTIVE DISORDERS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2021-08-27 |
Estimated end date | 2021-09-30 |
Actual end date | 2021-09-14 |
Shortage status | Resolved |
Updated date | 2021-09-16 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v5 | 2021-09-16 | French | Compare |
v4 | 2021-09-16 | English | Compare |
v3 | 2021-08-28 | English | Compare |
v2 | 2021-08-27 | French | Compare |
v1 | 2021-08-27 | English | Compare |
Showing 1 to 5 of 5